Inactive Instrument

Analyst Reco. Horizon Pharma Inc Nasdaq

Equities

US44047T1097

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jan. 16	Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders	CI
2023	Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla...

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Investors have China and central banks on their mind	23-08-28
Not too many jobs, please	23-08-04
Amgen Shares Slip 4.1% Following Decline in 4Q Profit, Revenue	23-02-01	DJ
UBS Adjusts Horizon Therapeutics Price Target to $116.50 From $76, Maintains Neutral Rating	22-12-13	MT
BMO Capital Downgrades Horizon Therapeutics to Market Perform From Outperform With $117 Price Target	22-12-13	MT
Guggenheim Downgrades Horizon Therapeutics to Neutral From Buy, Adjusts Price Target to $116.50 From $98	22-12-13	MT
SVB Securities Downgrades Horizon Therapeutics to Market Perform From Outperform, Adjusts Price Target to $116.50 From $88	22-12-13	MT
Wells Fargo Downgrades Horizon Therapeutics to Equalweight From Overweight, Adjusts Price Target to $116.50 From $118	22-12-13	MT
Jitters Over Inflation Data, Rate Decisions Push European Bourses Lower Monday	22-12-12	MT
The last days before Christmas will be hectic	22-12-12
US Consumer Price Index, Fed Rate Decision in Focus as Exchange-Traded Funds, Stock Futures Rise Premarket Monday	22-12-12	MT
Futures rise ahead of CPI data, Fed rate decision in focus	22-12-12	RE
French Stocks Edge Lower Midday Monday to Jumpstart Big Week for Rate Decisions	22-12-12	MT
German Stocks Falter Midday Monday as Blockbuster Week for Rate Decisions Spur Market Unease	22-12-12	MT
European shares slip on fears over rising China COVID cases, await rate decisions	22-12-12	RE
European shares fall on caution ahead of cenbanks' rate decisions	22-12-12	RE
Piper Sandler Raises Price Target on Horizon Therapeutics to $110 From $90, Maintains Overweight Rating	22-12-07	MT
Is the job report good or bad news?	22-12-02
SVB Securities Adjusts Horizon Therapeutics' Price Target to $88 From $80, Keeps Outperform Rating	22-11-03	MT
UBS Adjusts Horizon Therapeutics Price Target to $76 From $71, Maintains Neutral Rating	22-11-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Horizon Pharma Inc Nasdaq

Equities

US44047T1097

Analyst Reco.

Filters